Portfolio
Overview

Watchlist
Overview


more

Portfolios Overview New Portfolio
Demo Portfolio
$71,645.00
Total Gain % 127.59%
Total Gain $21,645.00
Total Realised % 0.00%
Total Realised $0.00
Back
Watchlists Overview New Watchlist
Targets
48 Average Rating
Number of Companies 3
Date Created 04 Mar, 2015
Back
Portfolio Summary
Demo Portfolio
Market Value $71,645.00
Total Gain $21,645.00
(127.59%)
Value $38,610.00
Close Price (04 May) $128.70
Unrealised P/L (%) 127.59%
Unrealised P/L $21,645.00
Total $71,645.00
$21,645.00
Back
Back
Watchlist Summary
Targets
Short Name TGTS
Date Created 04 Mar, 2015
Current Price $48.24
Added Price $43.28
STRIDE Rating 50
Value Change (%) 11.46%
Current Price $34.32
Added Price $34.56
STRIDE Rating 32
Value Change (%) -0.69%
Current Price $28.67
Added Price $29.66
STRIDE Rating 67
Value Change (%) -3.34%
Total Buy0
Total Hold2
Total Sell1
Back
Back
Filter
Include in Feed
My Portfolios
My Watchlists
STRIDE Lists
Filter Feed By
STRIDE 3D VI
Activity
Upcoming
Warning
Back
Company FilterClear All
Filter by Company Descriptions
Filter by STRIDE Scores
Strength
to
Timing
to
Returns
to
Intrinsic Value
to
Dividends
to
Earnings Predictability
to
Rating
to
Back
Options
Add To Watchlist
Company Info (Sample)
Options
Add To Watchlist

Accentia Biopharmaceuticals, Inc.

Accentia Biopharmaceuticals, Inc.
Pharmaceuticals, Biotechnology and Life Sciences : Biotechnology.
ABPI on Pink Sheets LLC.
Price in US Dollar, all financial data originally reported in US Dollar.
Founded in 2002, the business is 13 years old.
The business last filed accounts on the 26 Dec, 2012.
Company website: www.accentia.net
Show Company Details
STRIDE Rating
00
Buy
Hold
Sell
United States, Micro Cap
Market Capitalisation: $0.35M
Total Enterprise Value: Free Trial
Accentia Biopharmaceuticals, Inc., a biotechnology company, primarily discovers, develops, and commercializes immunotherapies to treat autoimmune related diseases and cancer in the United States. The company develops Cyrevia as a system of care for various autoimmune diseases; BiovaxID as a personalized therapeutic cancer vaccine to treat non-Hodgkin’s lymphoma, follicular lymphoma, mantle cell lymphoma, and other B-cell cancers; and SinuNasal lavage system as a medical device for chronic sinusitis. It also manufactures and sells a range of cell culture systems used for the production cell culture products, including HF Primer, a cell culture system for producing small, research, and development quantities of cell culture products from mammalian cell lines; Multi-6 for producing six monoclonal antibodies; AutovaxID, an automated cell culture system for production of personalized cell-based treatments and various additional vaccines; Acusyst-miniMax system, which offers two single-use disposables options to meet various production requirements; Acusyst-Maximizer, a system for process development and routine productions; and Acusyst-Xcellerator, a production-scale cell culture system. In addition, the company manufactures mammalian cell culture products, such as whole cells, recombinant and secreted proteins, and monoclonal antibodies, as well as provides related services in developing cell production process protocols, cell line optimization, cell culture production optimization, media evaluation, and other related services. Further, it sells hollow fiber bioreactors, cultureware, tubing sets, and other disposable products and supplies. The company provides its cell culture products and services to biopharmaceutical and biotechnology companies, medical schools, universities, research facilities, hospitals, and public and private laboratories. Accentia Biopharmaceuticals, Inc. was founded in 2002 and is headquartered in Tampa, Florida. Read More
Company Feed
03 May STRIDE has calculated that this business has no True Book Value. The STRIDE view of the balance sheet graph will not balance as we believe there is a 'hole' in the balance sheet. Proceed with caution.
03 May This business has not reported earnings in over 12 months so STRIDE cannot give it a valuation - please exercise caution & check all dates to ensure reporting is accurate and timely.
03 May This business has not reported earnings in over 9 months so while STRIDE can give it a valuation, we won't include it as a STRIDE Target - please exercise caution & check all dates to ensure you are dealing with current information.
Price & Valuation Info
Price Quote on 4th May '15
$0.0040 -0.00(-11.11%)
52 Week Range
0.0011
0.027
Interactive STRIDE chart with history.
Only available to subscribers.
Free Trial now.
Performance
1 month 0.00 (0%)
year-to-date 0.00 (66.67%)
1 year -0.00 (-24.53%)
Show More Valuation Info
Momentum
vs 52week high 15%
vs 50d SMA 0
vs 200d SMA0
STRIDE Valuations
Consider Buy Free Trial
Fair Value Free Trial
Consider Sell Free Trial
Price/Adj. Earnings Free Trial
Price/Adj FCF Free Trial
Price/Adj. TBV Free Trial
Forecast Growth Free Trial
Other Valuations
Price/Book Free Trial
Price/Tangible Book Free Trial
Price/Sales Free Trial
Price/Earnings Free Trial
Price/Free Cashflow Free Trial
EV/EBITDA Free Trial
Dividend Yield Free Trial
Volume
Ave. Vol. last 6 months
Hide Extra Info
Scores
S
Strength
T
Timing
R
Returns
I
Intrinsic Value
D
Dividends
E
Earnings Predictability
Other Metrics
Altman Z-Score (Bankruptcy)
Greenblatt Rank (Magic Formula)
Piotroski F-Score (Financial Health)
Beneish M-Score (Earnings Manipulation)
Financials Free Trial
To The Top
Company Options
Add To Watchlist
Watchlists:
Targets
Options
Price Alert Email:
Price to alert at:*
When to alert:*
Cancel
Save
Price Alerts Configured:
Back

Portfolio
Overview

Watchlist
Overview

Feed
Filter


more